[Genotoxicity of a standardized Hypericum extract].

The genotoxic potential of plant-derived compounds remains a key concern in drug development and dietary supplement safety. While bacterial assays frequently detect mutagenic activity, these results often fail to predict mammalian cell responses. St. John's wort contains hypericin and flavonoids like quercetin, which have raised questions about their safety. Prior research has shown hypericin can induce DNA damage in bacterial systems, but mammalian data remains limited. That uncertainty drives the need for comprehensive testing in relevant biological models. No prior work had resolved whether these compounds pose genotoxic risks in human cells. This gap motivated researchers to evaluate a standardized Hypericum extract using mammalian cell systems. The study aimed to clarify whether findings from bacterial tests accurately reflect human risk. This work builds on prior knowledge while addressing a critical safety question.

The study aimed to assess the genotoxic potential of a standardized Hypericum extract in mammalian cell systems. Researchers focused on resolving whether bacterial test results accurately predict human risk. They selected multiple in-vitro and in-vivo assays to evaluate DNA damage and chromosomal abnormalities. The goal was to determine if the extract induces mutagenic effects in mammalian cells. This approach allowed comparison between bacterial and mammalian responses. The study also sought to clarify the relevance of prior bacterial findings. By using Syrian hamster embryo cells and mouse models, the team tested for mutagenicity and chromosomal changes. The results would help establish safer use parameters for Hypericum-based supplements.

The team used HGPRT assays to detect gene mutations in mammalian cells. They also performed UDS tests to measure unscheduled DNA synthesis. A cell transformation assay with Syrian hamster embryo cells was conducted. In-vivo tests included the mouse fur spot assay and a chromosome aberration test in Chinese hamster bone marrow. The Hypericum extract was standardized to ensure consistent dosing. Researchers followed established protocols for each test system. All experiments were conducted under controlled laboratory conditions. The results were compared against known mutagenic and non-mutagenic controls.

All in-vitro tests showed no evidence of mutagenic activity in mammalian cells. The HGPRT assay detected no gene mutations in treated cells. The UDS test found no increased DNA repair activity. Cell transformation assays also yielded negative results. In-vivo tests confirmed these findings in live animal models. The mouse fur spot test showed no increased mutation frequency. Bone marrow chromosome analysis revealed no structural abnormalities. These results suggest the extract does not induce genotoxic effects in mammals.

The authors concluded that the Hypericum extract does not exhibit mutagenic potential in mammalian systems. Their findings suggest bacterial test results may not accurately predict human risk. The study supports the view that short-term bacterial assays have limited relevance for mammalian genotoxicity. Researchers emphasized the importance of using mammalian cell models for safety assessments. The negative results across multiple test systems strengthen this conclusion. These findings may inform regulatory decisions about Hypericum-based supplements. The authors propose further studies to explore long-term effects. Their work highlights the need for multi-model testing in natural product safety evaluation.